健择联合顺铂治疗老年晚期非小细胞肺癌患者的临床疗效观察

为了观察健择联合顺铂治疗老年(≥60岁)晚期(Ⅲ期及Ⅳ期)非小细胞肺癌(NSCLC)的疗效和毒副反应,探索适于老年人NSCLC的治疗方案。将48例患者分为治疗与观察两组,治疗组23例,d1、d8。健择1200mg/m2,静脉滴入,d1、d8;给予顺铂100mg/m2,静脉滴入,d1、d8。28d为1个周期。对照组25例采用单纯支持对症治疗。治疗组完全缓解(CR)4例,部分缓解(PR)7例,稳定(SD)8例,进展(PD)4例,有效率47·8%;对照组完全缓解(CR)0例,部分缓解(PR)2例,有效率8·0%,两组经统计学比较,差异有统计学意义,P<0·05。治疗组毒副反应有白细胞下降和血小板减少。初步研究的结果提示,健择联合顺铂治疗老年晚期NSCLC疗效较高,毒性可耐受。

Clinical study of therapeutic efficacy of gemcitabined combined with cisplatin for advanced non-small cell lung cancer in elderly patients

The objective of this study was to evaluate the efficacy, toxicity of gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Twenty-three patients in the chemotherapy group with gemcitabine (1 200 mg/m~2 iv infusion at 1 and 8) and cisplatin (100 mg/m~2 iv infusion at 1 and 8), as a intravenous infusion every 28 days. Twenty-five patients in the control group received supportive therapyonly. In the chemotherapy group, CR was in 4 case, PR 7 cases, SD 8 cases, PD 4 cases, and the response rate was 47.8%; in the contral group, there was on CR and PR was in 2 cases, and the response rate was 8.0%. There was a significant difference between the two groups, P<0.05. The toxicities were leukopenia and thrombocytopenia in. the contral group in conclusion, the combination of gemcitabine and cisplatin is a feasible,well-tolerated and effective scheme in the treatment of advanced non-small cell lung cancer in elderly patients.